Northland Upgrades Esperion Therapeutics (ESPR) to Market Perform. 'Potential Resolution of DSE Litigation as Catalysts'
August 1, 2023 2:01 PM
Northland Capital Markets analyst Carl Byrnes upgraded Esperion Therapeutics (NASDAQ: ESPR) from Underperform to Market Perform with a price target ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
